Sentrimed, Inc. filed a Form D with the Securities and Exchange Commission on 2026-05-13.
Sentrimed, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 13, 2026. The filing reports $250K sold. Its industry group is Biotechnology. It names William Ragatz (Executive Officer, Director), Bradley Galer (Director), Jack Goldberg (Executive Officer, Director) (SEC Form D, May 13, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Sentrimed, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-05-13 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Sentrimed, Inc.
Free to see. No signup.
More on the people and the money behind Sentrimed, Inc., from the filings we hold.
Biotechnology raises by companies based in New Jersey, filed within 90 days of this one, largest first.
Get an email when Sentrimed, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Sentrimed, Inc. raises, hires or launches. No email unless you switch it on.
Watch Sentrimed, Inc. →Get the full cited report on Sentrimed, Inc.
What the filing shows about Sentrimed, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sentrimed, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Sentrimed, Inc.'s address as 107 Gilbreth Parkway, Mullica Hill, NJ 08062.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Sentrimed, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Sentrimed, Inc. is a registered filer with the SEC (CIK 2014313) and has filed since 2024-03-07. 2 filings are on record, the latest on 2026-05-13.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Sentrimed, Inc.'s Form D of 2026-05-13 names William Ragatz, Bradley Galer, Jack Goldberg and 5 more as its officers, directors or promoters.
Its new offerings report $750K sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $250K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
News From Sentrimed Sentrimed is a clinical-stage biopharmaceutical company creating safer, oral oncology therapies that target podoplanin (PDPN), a prognostic cancer biomarker. PDPN is a transmembrane glycoprotein receptor that enables tumor cells to proliferate and migrate. This biomarker appears early in cancer transformation, persists
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
William Ragatz is named as Executive Officer and Director on the Form D that Sentrimed, Inc. filed with the SEC on 13 May 2026, one of 8 people that filing names.
Bradley Galer is named as Director on the Form D that Sentrimed, Inc. filed with the SEC on 13 May 2026, one of 8 people that filing names.
Jack Goldberg is named as Executive Officer and Director on the Form D that Sentrimed, Inc. filed with the SEC on 13 May 2026, one of 8 people that filing names.
Mari Yin is named as Executive Officer and Director on the Form D that Sentrimed, Inc. filed with the SEC on 13 May 2026, one of 8 people that filing names.
Gary Goldberg is named as Executive Officer on the Form D that Sentrimed, Inc. filed with the SEC on 13 May 2026, one of 8 people that filing names.
Arye Rosen is named as Executive Officer on the Form D that Sentrimed, Inc. filed with the SEC on 13 May 2026, one of 8 people that filing names.
Christopher Leonard is named as Executive Officer on the Form D that Sentrimed, Inc. filed with the SEC on 13 May 2026, one of 8 people that filing names.
Tabbetha Dobbins is named as Director on the Form D that Sentrimed, Inc. filed with the SEC on 13 May 2026, one of 8 people that filing names.
8 people named on the filing — 6 holding an executive role and 2 as directors only.
Named as of the 2026-05-13 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Sentrimed, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sentrimed, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sentrimed, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Sentrimed, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Sentrimed, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-25 (sentrimed.com).
Each opens in a new tab, filled in for Sentrimed, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/sentrimed-inc-form-d-26000002